Milk ribonuclease-enriched lactoferrin induces positive effects on bone turnover markers in postmenopausal women

Osteoporosis International

Volumn 20, Issue 9, 2009, Pages 1603-1611

  Bharadwaj, S ^a   Naidu, A G T ^a   Betageri, G V ^b   Prasadarao, N V ^c   Naidu, A S ^a  

^a N terminus Research Laboratory   (United States)

^b WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Lactoferrin; Osteoporosis; Postmenopause; Ribonuclease

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; DEOXYPYRIDINOLINE; LACTOFERRIN; OSTEOCALCIN; PLACEBO; RIBONUCLEASE; RIBONUCLEASE PLUS LACTOFERRIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS LINKING; DIET SUPPLEMENTATION; FEMALE; HEALTH STATUS; HUMAN; MILK; NORMAL HUMAN; OSSIFICATION; OSTEOLYSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; URINALYSIS; URINE LEVEL;

ALKALINE PHOSPHATASE; AMINO ACIDS; ANIMALS; BIOLOGICAL MARKERS; BONE REMODELING; BONE RESORPTION; CALCIUM, DIETARY; COLLAGEN TYPE I; DIETARY SUPPLEMENTS; FEMALE; HUMANS; LACTOFERRIN; MIDDLE AGED; MILK; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; POSTMENOPAUSE; RIBONUCLEASES;

EID: 68949212053     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-0839-8     Document Type: Article

References (45)

1. U Melton EA Chrischilles C Cooper, et al 1992 How many women have osteoporosis? J Bone Miner Res 7 1005 1010
2. LJ Melton 3rd EJ Atkinson MK O'Connor, et al 1998 Bone density and fracture risk in men J Bone Miner Res 13 1915
3. JA Collins JM Blake PG Crosignani 2005 Breast cancer risk with postmenopausal hormonal treatment Hum Reprod Update 11 545 560
4. DM Herrington TD Howard 2003 Hormone therapy and heart disease: from presumed benefit to potential harm N Engl J Med 349 5519 5521
5. R Makins A Ballinger 2003 Gastrointestinal side effects of drugs Expert Opin Drug Safety 2 421 429
6. H Kawakami 2005 Biological significance of milk basic protein (MBP) for bone health Food Sci Technol 11 1 8
7. S Aoe Y Toba J Yamamura, et al 2001 Controlled trial of the effects of milk basic protein (MBP) supplementation on bone metabolism in healthy adult women Biosci Biotechnol Biochem 65 913 918
8. J Yamamura S Aoe Y Toba, et al 2002 Milk basic protein (MBP) increases radial bone mineral density in healthy adult women Biosci Biotechnol Biochem 66 702 704
9. Y Morita H Matsuyama A Serizawa, et al 2008 Identification of angiogenin as the osteoclastic bone resorption-inhibitory factor in bovine milk Bone 42 380 387
10. J Glowacki 1998 Angiogenesis in fracture repair Clin Orthop 355S S82 S89
11. RAD Carano E Filvaroff 2003 Angiogenesis and bone repair Drug Discov Today 8 980 989
12. J Cornish KE Callon D Naot, et al 2004 Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vitro Endocrinology 145 4366 4374
13. D Naot 2005 Lactoferrin: a novel bone growth factor Clin Med Res 3 93 101
14. Naidu AS (2008) Angiogenin complexes (ANGex) and uses thereof. US Patent Application No. 20080255340
15. Naidu AS (2008) Immobilized angiogenin mixtures and uses thereof. US Patent Application No. 20080254018
16. B Gomez Jr S Ardakani J Ju, et al 1995 Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum Clin Chem 41 11 1560 1566
17. PD Delmas D Stenner HW Wahner, et al 1983 Assessment of bone turnover in postmenopausal osteoporosis by measurement of serum bone gla-protein J Lab Clin Med 102 470 476
18. JD Clemens, et al 1997 Evidence that serum NTx (collagen type I N-telopeptides) can act as immunochemical marker of bone resorption Clin Chem 43 2058 2063
19. PD Delmas A Schlemmer E Gineyts, et al 1991 Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured in iliac crest biopsy in patients with vertebral osteoporosis J Bone Miner Res 6 639 644
20. D Heinegard G Tiderstrom 1973 Determination of serum creatinine by a direct colorimetric method Clin Chim Acta 43 305
21. Zar JH (1999) Biostatistical analysis, 4th edn. Prentice Hall, NJ, p 475
22. R Eastell N Mallinak S Weiss, et al 2000 Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women J Bone Miner Res 15 594 598
23. JK Scariano RH Glew CE Bou-Serhal, et al 1998 Serum levels of cross-linked N-telopeptides and aminoterminal propeptides of type I collagen indicate low bone mineral density in elderly women Bone 23 471 477
24. BJ Gertz JD Clemens SD Holland, et al 1998 Application of a new serum assay for type i collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment Calcif Tissue Int 63 102 106
25. JD Clemens MV Herrick FR Singer, et al 1997 Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption Clin Chem 43 2058 2063
26. KM Prestwood DL Thompson AM Kenny, et al 1999 Low dose estrogen and calcium have an additive effect on bone resorption in older women J Clin Endocrinol Metab 84 179 183
27. HN Rosen RA Parker SL Greenspan, et al 2004 Evaluation of ability of biochemical markers of bone turnover to predict a response to increased doses of HRT Calcif Tissue Int 74 415 423
28. FN Ton SC Gunawardene H Lee, et al 2005 Effects of low-dose prednisone on bone metabolism J Bone Miner Res 20 464 470
29. SL Greenspan R Parker L Ferguson, et al 1998 Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial J Bone Mineral Res 13 1431 1438
30. P Garnero WJ Shih E Gineyts, et al 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment J Clin Endocrinol Metab 79 1693 1700
31. IR Reid J Lucas D Wattie, et al 2005 Effects of a β-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial J Clin Endocrinol Metab 90 5212 5216
32. P Chen JH Satterwhite AA Licata, et al 2005 Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis J Bone Miner Res 20 962 970
33. YA Suzuki B Lonnerdal 2002 Characterization of mammalian receptors for lactoferrin Biochem Cell Biol 80 75 80
34. A Grey T Banovic Q Zhu, et al 2004 The low-density lipoprotein receptor-related protein 1 is a mitogenic receptor for lactoferrin in osteoblastic cells Mol Endocrinol 18 2268 2278
35. OP Shestenko SD Nikonov NP Mertvetsov 2001 Angiogenin and its functions in angiogenesis Mol Biol 35 294 314
36. CH Chesnut III MR McClung KE Ensrud, et al 1995 Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling Am J Med 99 144 152
37. B Ettinger DM Black BH Mitlak, et al 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial JAMA 282 637 645
38. EG Lufkin MD Whitaker T Nickelsen, et al 1998 Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial J Bone Miner Res 13 1747 1754
39. PJ Meunier DO Slosman PD Delmas, et al 2002 Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis-a 2-year randomized placebo controlled trial J Clin Endocrinol Metab 87 2060 2066
40. SA Jamal SR Cummings GA Hawker 2004 Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial J Bone Miner Res 19 1512 1517
41. F Cosman 2006 Anabolic therapy for osteoporosis: parathyroid hormone Curr Rheumat Rep 8 63 69
42. S Asirvatham C Sebastian U Thadani 1998 Choosing the most appropriate treatment for stable angina. Safety considerations Drug Saf 19 23 44
43. JL Vahle M Sato GG Long, et al 2002 Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for two years and relevance to human safety Toxicol Pathol 30 312 321
44. AB Hodsman DC Bauer DW Dempster, et al 2005 Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use Endocr Rev 26 688 703
45. MC Hochberg S Greenspan RD Wasnich, et al 2002 Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents J Clin Endocrinol Metab 87 1586 1592